NFKB1 and myelodysplastic syndrome: In summary, the immune profiling described here could aid in refining MDS stratification, particularly in distinguishing patients who may benefit from immune‐modulating therapies such as IRAK4 inhibitors or NF‐κB‐targeting agents.